Gout
Conditions
Interventions
Gout Observation Group:None
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 18 - 75 years old, gender not restricted; 2. Meets the 2015 ACR/EULAR classification criteria for gout; 3. Had at least 2 acute gout attacks within 1 year prior to screening; 4. Serum uric acid (SUA) >= 420 µmol/L; 5. Coronary CT angiography (CCTA) examination meets the following criteria: no history of iodine contrast agent allergy; renal function meets the requirements for contrast imaging (eGFR >= 45 mL/min/1.73m^2, based on the CKD-EPI formula); 6. Those who have used uric acid-lowering drugs in the past (such as febuxostat, allopurinol) must have been taking the medication regularly for >= 1 month and the SUA fluctuation <= 20%, and agree to continue the original treatment plan during the study period; those who have not used uric acid-lowering drugs in the past agree to receive the uric acid-lowering drug treatment plan specified in this study during the study period; 7. Voluntarily sign the informed consent form and be able to cooperate with the 12-month follow-up.
Exclusion criteria
Exclusion criteria: 1. Acute gout combined with severe complications: joint cavity abscess (ultrasound shows fluidic dark area + positive bacterial culture), rhabdomyolysis (creatine kinase > 5 times the upper limit of normal + muscle pain / tea-colored urine); 2. Unable to stabilize after standard treatment in the acute phase (VAS persists > 2 points for more than 14 days, or severe adverse reactions such as gastrointestinal ulcers, elevated liver enzymes, etc. occur); 3. Acute cardiovascular events occurred within the past 6 months (acute myocardial infarction, stroke, acute coronary syndrome, etc.); 4. Severe heart failure (NYHA grade III-IV), malignant arrhythmia (such as ventricular tachycardia, history of ventricular fibrillation); 5. Iodine contrast agent contraindications: history of allergy, uncontrolled hyperthyroidism, eGFR 3 times the upper limit of normal; estimated glomerular filtration rate < 30 mL/min/1.73m^2); 8. Within the past 3 months, used biological agents such as IL-1/IL-6 inhibitors, or within the past 1 month, used immunosuppressants (such as methotrexate, cyclosporine); 9. Allergic to study-related drugs and their components: IL-1 inhibitors, etoricoxib, colchicine, febuxostat; 10. Pregnant or lactating women; fertile women / men refusing to take effective contraceptive measures; or those planning to get pregnant during the study; 11. Complicated with malignant tumors (diagnosed within the past 5 years), unable to cooperate with follow-up due to mental illness; 12. Expected survival period < 12 months, severe coagulation dysfunction and other conditions not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FAI; | — |
Secondary
| Measure | Time frame |
|---|---|
| The recurrence rate of gout;Intima-media thickness (IMT);hs-CRP;SUA compliance rate;The volume of gout stones;IL-1ß;Serum uric acid; | — |
Countries
China
Contacts
Public ContactChen Ying
The Affiliated Hospital of Qingdao University
Outcome results
None listed